Affymax Falls After Firing 75% of Workers

Affymax Inc. (AFFY) dropped to its lowest value ever after the company said it will fire three-quarters of its workforce and hire a bank to evaluate a possible sale or bankruptcy after the recall of its only drug.

Affymax plunged 64 percent to $1.05 at the close in New York, its lowest price since the shares began trading in December 2006. The Palo Alto, California-based company has fallen 73 percent in the past 12 months.

About 230 positions, including the medical affairs field organizations, will be cut as a reason is sought for the reported hypersensitivity reactions to anemia treatment Omontys that caused the recall, the company said yesterday in a statement. Affymax said the bank will consider options including a sale of the company or assets, restructuring, winding down operations and bankruptcy.

“While this decision was extremely difficult, aligning and managing our limited resources around our product investigation is our most important priority,” John Orwin, Affymax’s chief executive officer, said in the statement.

On Feb. 25, Affymax fell the most ever after recalling Omontys, which is used by kidney dialysis patients. Affymax and its partner Osaka, Japan-based Takeda Pharmaceutical Co. (4502) at the time said they were analyzing data from three patients who died to find a cause for the reactions.

Affymax said in a separate filing that it is unable to estimate how long the investigation will take and whether the company would be able to finish it.

“With limited funds and resources, the company may not be able to complete the investigation or ever identify the causes of the safety concerns,” Affymax said in the filing.

To contact the reporter on this story: Ryan Flinn in San Francisco at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.